A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer (REAL3).

Trial Profile

A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer (REAL3).

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Panitumumab (Primary) ; Capecitabine; Epirubicin; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms REAL3
  • Most Recent Events

    • 11 Oct 2016 Results assessing association between genomic loss of heterozygosity and survival in the REAL3 trial (n=86) presented at the 41st European Society for Medical Oncology Congress
    • 30 May 2014 Quality of life results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top